DAILYPEPTIDE GUIDE
Clinical Pipeline

ARA-290

Cibinetide

ARA-290 is a clinical-stage asset. Trial status and sponsor-reported findings remain time-sensitive and indication-specific.

Compare
EvidenceTier 2
RegulatoryInvestigational
SafetyUncertain or Concerning
Clinical phasePhase 2
01

Overview

ClassInnate repair receptor agonist
Sponsor / developerAraim Pharmaceuticals
Review statusReviewed
Record IDPEP-031
02

Plain-language guide

What it was designed or studied for

Designed for research into Small-fiber neuropathy, Inflammatory conditions. It remains investigational for these uses.

How it works, simply

It interacts with a specific cell-signaling pathway. The measured clinical effect depends on the exact molecule, formulation, population and quality of evidence.

This simplified explanation is educational context, not a treatment recommendation or a substitute for the clinical evidence below.
03

Clinical mechanism

Derived from erythropoietin helices and designed to engage tissue-protective signaling without erythropoiesis.

Mechanism plausibility is not the same as demonstrated clinical benefit.
04

Applications

  • Small-fiber neuropathy
  • Inflammatory conditions
05

Human evidence

Early or mid-stage human data exist, but confirmation, replication or long-term follow-up remains incomplete.

Tier 2
06

Preclinical evidence

Mechanistic and preclinical findings are tracked separately and are not treated as proof of human clinical benefit.

MAP

Muscle & recovery profile

Each signal is scored independently from 0–5. There is no composite “best” score.

Growth relevance0/5
Preservation relevance1/5
Recovery relevance3/5
Mitochondrial support1/5
Connective tissue1/5
Human-data depth2/5
Safety confidence2/5
Evidence–hype gap2/5

Evidence classes

  • Phase 2 human evidence
  • Phase 1 / early human evidence
  • Preclinical animal evidence

What has been studied

  • Early studies have examined neuropathy and tissue-protective outcomes.

What is not established

  • Muscle recovery, athletic performance and approved clinical benefit are not established.

Studied populations

  • People with neuropathic or inflammatory conditions in clinical research

Major limitations

  • Muscle-specific outcomes may be secondary, exploratory or absent from available studies.
  • Findings from one population, formulation or indication should not be generalized to another.

Evidence-source categories: primary regulatory record, clinical trial registry, peer reviewed literature. These editorial source categories require record-level primary links before publication-grade citation export.

06

Regulatory status

Investigational. Regulatory status is product- and jurisdiction-specific and does not automatically follow from an evidence score.

07

Safety

Uncertain or Concerning

  • Adverse effects vary by product and indication
  • Contraindications and interactions require label review
08

Interactions

Review the current product label and indication-specific literature for pharmacologic and absorption interactions.

09

Treatment pattern

Treatment patterns are product-, indication- and clinician-specific; this educational profile does not provide dosing guidance.

10

Manufacturing and quality

Approved-product identity, formulation and quality controls must not be extrapolated to compounded or RUO copies.

12

Sources

  1. 01
    Primary regulatory record

    Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.

  2. 02
    Clinical trial registry

    Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.

  3. 03
    Peer-reviewed literature

    Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.

13

Gaps and unverified claims

  • Long-term outcomes and real-world safety are not yet established.
  • Current phase and catalysts require primary-source confirmation.
14

Last reviewed

August 5, 2026 · Reviewed